SCHEMBL5886356

SCHEMBL5886356

CS(=O)(=O)c1cccc2c1C=CC(=O)C2=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRC P08575 4/20 0.49
ALDH1A1 P00352 4/20 0.42
IDO1 P14902 3/20 0.42
PTPN1 P18031 3/20 0.42
KDM4E B2RXH2 3/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
MAPT P10636 2/20 0.42
THRB P10828 2/20 0.42
HPGD P15428 2/20 0.42
ALOX15 P16050 2/20 0.42
RECQL P46063 2/20 0.42
HSD17B10 Q99714 2/20 0.42
LMNA P02545 1/20 0.42
BCHE P06276 1/20 0.42
POLB P06746 1/20 0.42
PKM P14618 1/20 0.42
ACHE P22303 1/20 0.42
CES1 P23141 1/20 0.42
PTPN22 Q9Y2R2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14488751 0.82 BAZ2B (0.36) PTPRCALDH1A1KDM4EKMT2ABAZ2B
SCHEMBL819288 0.82 BAZ2B (0.33) PTPRCALDH1A1KDM4EKMT2ABAZ2B
SCHEMBL9573746 0.81 STAT3 (0.46) PTPRCALDH1A1IDO1PTPN1KDM4E
SCHEMBL2400017 0.81 PTPRC (0.45) PTPRCALDH1A1IDO1PTPN1KDM4E
SCHEMBL7070987 0.81 PTPRC (0.49) PTPRCALDH1A1IDO1PTPN1KDM4E
SCHEMBL30485567 0.81 PTPRC (0.49) PTPRCALDH1A1IDO1PTPN1KDM4E
SCHEMBL278528 0.80 PTPRC (0.33) PTPRCIDO1CDC25BPIN1MAOA
Hydrochloric Acid SCHEMBL27744031 0.80 PTPRC (0.47) PTPRCALDH1A1IDO1PTPN1KDM4E
Nitrogen SCHEMBL27516869 0.79 PTPRC (0.46) PTPRCALDH1A1IDO1PTPN1KDM4E
SCHEMBL818753 0.78 BRD9 (0.31) PTPRCALDH1A1BAZ2BBAZ2ABRD9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1304380-C Benzo[a]henazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II XENOVA LTD (GB) 2007-03-14 CN disclosed
US-7132419-B2 Pharmaceutical compounds XENOVA LIMITED (GB) 2006-11-07 US disclosed
US-20050143383-A1 Pharmaceutical compounds XENOVA LIMITED (GB) 2005-06-30 US disclosed
CN-1433406-A Benzo [ a ] phenazine-11-amide derivatives and their use as combined topoisomerase I and II inhibitors XENOVA LTD (GB) 2003-07-30 CN disclosed
US-20030139409-A1 Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II XENOVA LIMITED (GB) 2003-07-24 US disclosed
EP-1240148-A1 BENZO[A]PHENAZIN-11-CARBOXAMIDE DERIVATIVES AND THEIR USE AS JOINT INHIBITORS OF TOPOMERASE I AND II Xenova Limited (GB) 2002-09-18 EP disclosed
WO-2001046157-A1 BENZO[A]PHENAZIN-11-CARBOXAMIDE DERIVATIVES AND THEIR USE AS JOINT INHIBITORS OF TOPOMERASE I AND II XENOVA LIMITED (GB) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143383-A1 Pharmaceutical compounds CHRNA10, OPRM1, SCN10A PTPRC 3881/4885ALDH1A1 3766/4885IDO1 3508/4885
US-20030139409-A1 Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II TOP1, TOP2A, TOP2B PTPRC 2451/4885ALDH1A1 2334/4885IDO1 947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.